Taisho Pharmaceutical Holdings Co Ltd represents a strong commitment to providing quality healthcare products and improving the well-being of individuals. Their corporate philosophy revolves around innovation, ethical practices, and customer satisfaction. With a focus on research and development, Taisho Pharmaceutical aims to create cutting-edge solutions that address various health concerns. The company's values include integrity, respect for diversity, and a dedication to social responsibility. By combining their expertise with a customer-centered approach, Taisho Pharmaceutical strives to make a positive impact on society through their pharmaceutical and healthcare offerings.

Taisho Pharmaceutical Holdings Co Ltd is primarily present in Japan.

Taisho Pharmaceutical Holdings Co Ltd has achieved several significant milestones throughout its history. One notable milestone was the acquisition of Bristol-Myers Squibb's OTC drug business in 2009, expanding its product portfolio and market presence. In 2011, Taisho successfully launched its flagship product, Lipovitan D, a popular energy drink that quickly gained popularity in the Japanese market. Additionally, the company has consistently focused on research and development, leading to the introduction of innovative pharmaceutical products. Taisho Pharmaceutical Holdings Co Ltd continues to foster strategic partnerships and expand its global presence, making it a leading player in the healthcare industry.

Taisho Pharmaceutical Holdings Co Ltd is a renowned pharmaceutical company with a rich history and notable background. Established in 1912, the company has been dedicated to improving healthcare and enhancing the well-being of individuals worldwide. With its headquarters in Tokyo, Japan, Taisho Pharmaceutical Holdings has expanded its operations to various countries, including the United States, China, and Southeast Asia. The company specializes in the research, development, manufacturing, and sales of a wide range of pharmaceutical products, including prescription drugs, OTC medications, and health-related products. Taisho Pharmaceutical Holdings Co Ltd has continuously strived for innovation and excellence, earning a reputation as a leading player in the global pharmaceutical industry.

The main competitors of Taisho Pharmaceutical Holdings Co Ltd in the market are Takeda Pharmaceutical Company Limited, Pfizer Inc., and GlaxoSmithKline plc.

Taisho Pharmaceutical Holdings Co Ltd is primarily active in the pharmaceutical industry.

The business model of Taisho Pharmaceutical Holdings Co Ltd revolves around the development, manufacture, and sale of pharmaceutical products. As a leading Japanese pharmaceutical company, Taisho focuses on research and innovation to provide high-quality medications to improve people's health and well-being. The company specializes in therapeutic areas such as internal medicine, dermatology, and nutraceuticals. Taisho Pharmaceutical Holdings Co Ltd strives to establish a strong presence in both domestic and international markets, ensuring accessibility to their diverse range of healthcare products. With a dedication to advancing medical solutions, Taisho remains committed to addressing society's healthcare needs effectively.

Taisho Pharmaceutical Holdings Co의 P/E 비율은 58.85입니다.

Taisho Pharmaceutical Holdings Co의 P/S 비율은 2.17입니다.

Taisho Pharmaceutical Holdings Co에 대한 AlleAktien 품질 점수는 2/10입니다.

예상되는 Taisho Pharmaceutical Holdings Co 매출은 324.97 조. JPY입니다.

예상되는 Taisho Pharmaceutical Holdings Co 이익은 11.97 조. JPY입니다.

Taisho Pharmaceutical Holdings Co Ltd is a Japanese company active in the pharmaceutical, healthcare, and cosmetics sectors. The company was established in 1912 and has its headquarters in Tokyo, Japan. The business model of Taisho Pharmaceutical focuses on the development, production, and sale of innovative products aimed at improving people's health and well-being. The company operates three main business fields: pharmaceuticals, healthcare, and cosmetics. In the pharmaceutical business, Taisho Pharmaceutical manufactures and distributes medications used to treat diseases and ailments. The company has a wide range of medications for cardiovascular diseases, diabetes, pain and inflammation, as well as viral and bacterial infections. The company utilizes advanced technologies and places a major emphasis on research and development to consistently bring the best medication to the market. The healthcare business of Taisho Pharmaceutical includes a range of products aimed at maintaining people's health and well-being. The company offers dietary supplements, vitamins, sports and fitness products, as well as health monitoring devices. These products are sold through various distribution channels such as pharmacies, drugstores, and online shops. In the cosmetics field, Taisho Pharmaceutical offers a wide range of products including skincare, haircare, and makeup products. The company has developed its cosmetics products using its pharmaceutical technologies and research to create the best products. These products are sold both in the Japanese market and internationally. In conclusion, Taisho Pharmaceutical's business model is focused on innovation, research, and development. The company aims to improve people's health and well-being by developing innovative products that cater to customer needs. With its diverse range of products and services, Taisho Pharmaceutical successfully operates in the pharmaceutical, healthcare, and cosmetics industries and will continue to serve customers worldwide in the future.

Taisho Pharmaceutical Holdings Co은(는) 연간 번의 배당을 통해 100 JPY의 배당금을 지급합니다.

Taisho Pharmaceutical Holdings Co의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Taisho Pharmaceutical Holdings Co의 ISIN은 JP3442850008입니다.

Taisho Pharmaceutical Holdings Co의 WKN은 A1JKG0입니다.

Taisho Pharmaceutical Holdings Co의 티커는 4581.T입니다.

지난 12개월 동안 Taisho Pharmaceutical Holdings Co은(는) 100 JPY 의 배당금을 지급했습니다. 이는 약 1.17 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Taisho Pharmaceutical Holdings Co은(는) 100.72 JPY의 배당금을 지급할 것으로 예상됩니다.

Taisho Pharmaceutical Holdings Co의 현재 배당 수익률은 1.17 %입니다.

Taisho Pharmaceutical Holdings Co은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Taisho Pharmaceutical Holdings Co은(는) 지난 16년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 100.72 JPY의 배당금이 예상됩니다. 이는 배당수익률 1.17 %에 해당합니다.

Taisho Pharmaceutical Holdings Co은 '건강' 섹터에 속합니다.

Taisho Pharmaceutical Holdings Co의 마지막 배당금을 50 JPY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Taisho Pharmaceutical Holdings Co는 100 JPY를 배당금으로 지급했습니다.

Taisho Pharmaceutical Holdings Co의 배당금은 JPY에 지급됩니다.